Here's why the Creso Pharma (ASX:CPH) share price is surging 6% today

The cannabis and psychedelics company released a positive update today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price is climbing today after its Canadian subsidiary announced it has secured approval to produce more psychedelic substances.

At the time of writing, Creso Pharma shares are in the green, up 6.25% trading at 10.2 cents.

Creso Pharma is a cannabis and psychedelics company with operations in Switzerland, Canada, Colombia, Israel and Australia. In July, Creso Pharma completed the acquisition of Canadian-based psychedelics company Halucenex Life Sciences.

Back view of a man lifting hish hands high in front of hemp plants grown for cannabis.

Image source: Getty Images

What did the company announce today?

Today, Creso Pharma had some positive news for the ASX market about Halucenex Life Sciences. Halucenex has secured an amendment to its dealer licence from Health Canada.

The company said this would enable it to produce psychedelic substances including psilocybin, ketamine, LSD, salvia divinorum, harmaline, salvinorin A, and MDMA.

Halucenex also plans to start growing its own botanical psilocybin and manufacturing psilocybin. And is looking to spearhead more research and development on botanic and synthetic psilocybin.

Halucenex will forward with a clinical trial investigating the use of psilocybin to treat post-traumatic stress disorder, pending regulatory approval.

Management commentary

Halucenex CEO Bill Fleming said:

We will now begin the steps towards synthetic psilocybin manufacture and botanical psilocybin growing immediately.

Both of these initiatives have the potential to deliver a number of commercial and research and development benefits and will shape future product development, clinical trials and potential licencing agreements.

Creso Pharma share price snapshot

The Creso Pharma share price has soared 62.70% over the past 12 months. This has outpaced the S&P/ASX 200 Index (ASX: XJO) which is up 9.8% over the same period.

However, in the 2021 year to date, the company's shares are in the red by around 43%. Creso Pharma shares are also down from the monthly high of 15 cents on 8 November.

The company's shares reached a 52-week high of 25.5 cents on 11 December 2020.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »